Association of the CHG Index with the onset, progression, and prognosis of cardiovascular-kidney-metabolic syndrome: findings from two large prospective cohorts
A simple three-number health marker can help predict who's at risk for heart, kidney, and metabolic disease years before symptoms appear.
The CHG index, a simple composite of cholesterol, HDL, and glucose, significantly predicts development of each component disease, stage-wise progression, and adverse outcomes across the entire cardiovascular-kidney-metabolic syndrome continuum in two large prospective cohorts (n=379,410 combined). Incorporating longitudinal CHG monitoring into routine health evaluations may enhance population-level CKM risk prediction and inform prevention strategies.
What the study was
- Study design
- Prospective cohort (UK Biobank n=370,916, median follow-up 16.5yr) + validation cohort (Beijing Anzhen Hospital n=8,494, median follow-up 645 days); Fine-Gray subdistribution hazards + causal forest ML
- Population
- General population free of CKM diseases (UKB) and patients with established CKM Stage 4 coronary artery disease (Beijing Anzhen)
- Sample size
- 379410
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Diabetologia et Metabolismus Syndrome
Why it surfaced
Two large prospective cohorts (combined n>379K) demonstrate CHG index tracks CKM syndrome continuum from incidence through progression and adverse outcomes. Simple 3-component index potentially implementable in routine screening. ML subgroup finding (greatest impact in low-inflammation/high-HbA1c) adds clinical targeting precision.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.